Drug Patents owned by Genentech Inc

1. Drug name - COTELLIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7803839 GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Nov, 2029

(7 years from now)

US10478400 GENENTECH INC Immediate-release tablets containing combimetinib and methods of making and using the same
Jun, 2036

(13 years from now)

US10590102 GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone
Jun, 2036

(13 years from now)

CN103524392A GENENTECH INC Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases
Oct, 2026

(4 years from now)

CN104892582B GENENTECH INC As Arylmethylazetidine For Mek Inhibitor For Treating Proliferative Diseases
Oct, 2026

(4 years from now)

CN104892582A GENENTECH INC As Azetidine Mek Inhibitors For The Treatment Of Proliferative Diseases
Oct, 2026

(4 years from now)

CN101365676B GENENTECH INC Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases
Oct, 2026

(4 years from now)

CN109053523A GENENTECH INC As Mek Inhibitors For The Treatment Of Proliferative Diseases Of Azetidine
Oct, 2026

(4 years from now)

CN109053523B GENENTECH INC Azdines As Mek Inhibitors For The Treatment Of Proliferative Diseases
Oct, 2026

(4 years from now)

CN103524392B GENENTECH INC As Mek Inhibitors For The Treatment Of Proliferative Diseases Of Azetidine
Oct, 2026

(4 years from now)

CN101365676A GENENTECH INC Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases
Oct, 2026

(4 years from now)

CN108135854B GENENTECH INC Immediate Release Tablet Containing Medicine And Method For Forming Tablet
Jun, 2036

(13 years from now)

CN108135854A GENENTECH INC Drug-Containing Immediate Release Tablets And A Method Of Forming A Tablet
Jun, 2036

(13 years from now)

IN200802771P1 GENENTECH INC Mek Inhibitors And Methods Of Thier Use
Oct, 2026

(4 years from now)

IN313177B GENENTECH INC Mek Inhibitors And Methods Of Thier Use
Oct, 2026

(4 years from now)

EP1934174B1 GENENTECH INC Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases
Oct, 2026

(4 years from now)

EP1934174A1 GENENTECH INC Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases
Oct, 2026

(4 years from now)

EP3316867A1 GENENTECH INC Immediate-Release Tablets Containing A Drug And Processes For Forming The Tablets
Jun, 2036

(13 years from now)

EP3316867B1 GENENTECH INC Immediate-Release Tablets Containing A Drug And Processes For Forming The Tablets
Jun, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8362002 GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases Oct, 2026

(4 years from now)

US11087354 GENENTECH INC Combination therapies Jun, 2034

(11 years from now)

Drugs and Companies using COBIMETINIB FUMARATE ingredient

Treatment: Method of using cobimetinib for the treatment of melanoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription

2. Drug name - ESBRIET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8383150 GENENTECH INC Granulate formulation of pirfenidone and pharmaceutically acceptable excipients Sep, 2026

(3 years from now)

US7767225 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients Sep, 2026

(3 years from now)

US7988994 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients Sep, 2026

(3 years from now)

US8753679 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients Sep, 2026

(3 years from now)

US7767700 GENENTECH INC Method of providing pirfenidone therapy to a patient Dec, 2027

(5 years from now)

US8420674 GENENTECH INC Method of providing pirfenidone therapy to a patient Dec, 2027

(5 years from now)

US7696236 GENENTECH INC Method of providing pirfenidone therapy to a patient Dec, 2027

(5 years from now)

US7566729 GENENTECH INC Modifying pirfenidone treatment for patients with atypical liver function Apr, 2029

(6 years from now)

US8609701 GENENTECH INC Pirfenidone treatment for patients with atypical liver function Apr, 2029

(6 years from now)

US7635707 GENENTECH INC Pirfenidone treatment for patients with atypical liver function Apr, 2029

(6 years from now)

US8592462 GENENTECH INC Pirfenidone treatment for patients with atypical liver function Apr, 2029

(6 years from now)

US8013002 GENENTECH INC Methods of administering pirfenidone therapy Jan, 2030

(7 years from now)

US7910610 GENENTECH INC Methods of administering pirfenidone therapy Jan, 2030

(7 years from now)

US8084475 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450 Jan, 2030

(7 years from now)

US8318780 GENENTECH INC Methods of administering pirfenidone therapy Jan, 2030

(7 years from now)

US8754109 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450 Jan, 2030

(7 years from now)

US7816383 GENENTECH INC Methods of administering pirfenidone therapy Jan, 2030

(7 years from now)

US8648098 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450 Jan, 2030

(7 years from now)

US8778947 GENENTECH INC Methods of administering pirfenidone therapy Aug, 2033

(10 years from now)

US10188637 GENENTECH INC Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same Mar, 2037

(14 years from now)

Drugs and Companies using PIRFENIDONE ingredient

Treatment: Method of administering a granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone as recited in claim 1, to treat idiopathic pulmonary fibrosis; Method of administering pirfenidone capsules to treat a fibrotic condition; Dose escalation over 14 days for treatment of idiopathic pulmonary fibrosis; Dose escalation over 14 days for treatment of a fibrosis condition; Dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis; Dosage modification following grade 2 abnormality in liver function biomarker alt or ast after pirfenidone administration, by administering a sub-1600 mg/day dose, followed by administering at least 1602 mg/day; dosing at least 1602 mg/day following grade 2 abnormality in liver function biomarker alt or ast after pirfenidone administration; dosage modification following grade 2 abnormality in liver function biomarker alt or ast after pirfenidone administration, by discontinuing pirfenidone, followed by administering at least 1602 mg/day; full daily dosing following grade 2 abnormality in liver function biomarker alt or ast after pirfenidone administration; dosage modification following grade 2 abnormality in liver function biomarker alt or ast after pirfenidone administration, by administering sub-2400 mg/day dose, followed by full daily dose; dosage modification following grade 2 abnormality in liver function biomarker alt or ast after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, followed by full daily dose; dosage modification following grade 2 abnormality in biomarker alt or ast after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, then sub-1600 mg/day, then at least 1602 mg/day; Dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, followed by 801 mg/day, dose, then 1602 mg/day in treatment of ipf; full daily dosing following grade 2 abnormality in liver function biomarker after pirfenidone administration in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, followed by administering full daily dose in treatment of ipf; dosing 1602 mg/day pirfenidone following grade 2 abnormality in liver function biomarker after pirfenidone administration in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering 801 mg/day followed by administering 1602 mg/day in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits followed by administering 1602 mg/day in treatment of ipf; Continued dosing or dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis; Method for administering pirfenidone to reduce drug interactions with fluvoxamine; Method for administering pirfenidone to reduce drug interactions with a strong inhibitor of cyp1a2; Method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing or avoiding another strong cyp1a2 inducer; Method for administering pirfenidone while avoiding or discontinuing concomitant use of a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme involved in pirfenidone metabolism; Method for administering pirfenidone to avoid reduced efficacy by avoiding smoking or by avoiding another strong cyp1a2 inducer; Method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing a strong cyp1a2 inducer; Dosage modification in treatment with pirfenidone to reduce drug interactions with ciprofloxacin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
267MG TABLET;ORAL Prescription
534MG TABLET;ORAL Discontinued
801MG TABLET;ORAL Prescription

3. Drug name - EVRYSDI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9586955 GENENTECH INC Compounds for treating spinal muscular atrophy
Feb, 2033

(10 years from now)

US9969754 GENENTECH INC Compounds for treating spinal muscular atrophy
May, 2035

(12 years from now)

CN104349777A GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

CN104349777B GENENTECH INC For Compound For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

CN106459092B GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

CN106459092A GENENTECH INC For Compound For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

IN201647038542A GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

IN334397B GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

EP3406252B1 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

EP2812004A2 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

EP2812004A4 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

EP2812004B1 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

EP3406252A1 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

EP3143025A1 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

EP3143025B1 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
May, 2035

(12 years from now)

Drugs and Companies using RISDIPLAM ingredient

Treatment: NA

Dosage: FOR SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
0.75MG/ML FOR SOLUTION;ORAL Prescription

4. Drug name - GAVRETO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10030005 GENENTECH INC Inhibitors of RET
Nov, 2036

(14 years from now)

CN108473468B GENENTECH INC Inhibitors Of Ret
Nov, 2036

(14 years from now)

CN108473468A GENENTECH INC Inhibitors Of Ret
Nov, 2036

(14 years from now)

Drugs and Companies using PRALSETINIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG CAPSULE;ORAL Prescription

5. Drug name - ROZLYTREK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9029356 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US8299057 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Mar, 2029

(6 years from now)

US9085565 GENENTECH INC Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(10 years from now)

US10738037 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(14 years from now)

CN106167485A GENENTECH INC Acetamidobenzamide, Compositions Containing Acetamidobenzamide And Preparation Method Of Acetamidobenzamide
Feb, 2020

(2 years ago)

CN101754956A GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

CN103923072A GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

CN103923072B GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

CN101754956B GENENTECH INC Substituted Indazole Derivatives Having Activity Of Kinase Inhibitors
Jul, 2028

(5 years from now)

CN104395308B GENENTECH INC N - [3 - (5, 5-Difluoro-Benzyl)--1H - Indazole - -3 - Yl] -4-(4-Methyl-Piperazine - -1 - Yl)--2-(Tetrahydro-Pyran - -4 - Ylamino) - Benzamide Preparation Method
May, 2033

(10 years from now)

CN104395308A GENENTECH INC N - [3 - (5, 5-Difluoro-Benzyl)--1H - Indazole - -3 - Yl] -4-(4-Methyl-Piperazine - -1 - Yl)--2-(Tetrahydro-Pyran - -4 - Ylamino) - Benzamide Preparation Method
May, 2033

(10 years from now)

CN109153669B GENENTECH INC New Crystal Form Of Benzamide Compound
May, 2037

(14 years from now)

CN109153669A GENENTECH INC N - [5 - (3, 5-Difluoro-Benzyl) -1H - Indazol - -3 - Yl]--4-(4-Methyl-Piperazin - -1 - Yl)--2-(Tetrahydropyran - -4 - Ylamino) - Form
May, 2037

(14 years from now)

IN281852B GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

IN201000870P4 GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

IN361050B GENENTECH INC Process For The Preparation Of N-[5-(3-5-Difluoro Benzyl)-1H-Indazol 3 Yl]- 4-(4 Methyl Piperazin -1- Yl) -2- (Tetrahydro Pyran -4- Ylamino) Benzamide
May, 2033

(10 years from now)

IN201409107P4 GENENTECH INC Process For The Preparation Of N [5 (3 5 Difluoro Benzyl) 1H Indazol 3 Yl] 4 (4 Methyl Piperazin 1 Yl) 2 (Tetrahydro Pyran 4 Ylamino) Benzamide
May, 2033

(10 years from now)

EP2855460A1 GENENTECH INC Process For The Preparation Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide
Oct, 2017

(4 years ago)

EP2176231B1 GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

EP2176231A1 GENENTECH INC Substituted Indazole Derivatives Active As Kinase Inhibitors
Jul, 2028

(5 years from now)

EP3290414B1 GENENTECH INC Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide
May, 2033

(10 years from now)

EP3333166B1 GENENTECH INC Process For The Preparation Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide
May, 2033

(10 years from now)

EP3333166A1 GENENTECH INC Process For The Preparation Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide
May, 2033

(10 years from now)

EP3290414A1 GENENTECH INC Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide
May, 2033

(10 years from now)

EP3464276A1 GENENTECH INC New Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydropyran-4-Ylamino)-Benzamide
May, 2037

(14 years from now)

EP3464276B1 GENENTECH INC New Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydropyran-4-Ylamino)-Benzamide
May, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9085558 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors Jul, 2028

(5 years from now)

US9255087 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors Jul, 2028

(5 years from now)

US8673893 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors Jul, 2028

(5 years from now)

US9616059 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors Jul, 2028

(5 years from now)

US9649306 GENENTECH INC Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide May, 2033

(10 years from now)

US10231965 GENENTECH INC Molecules for administration to ROS1 mutant cancer cells Feb, 2035

(12 years from now)

US10561651 GENENTECH INC Methods for treating neuroblastoma Feb, 2035

(12 years from now)

US11091469 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide May, 2037

(14 years from now)

US10398693 GENENTECH INC Pharmaceutical compositions and dosage forms Jul, 2038

(15 years from now)

Drugs and Companies using ENTRECTINIB ingredient

Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; treatment of ros1-positive non-small cell lung cancer; Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of neuroblastomas that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of ros1-positive non-small cell lung cancer; treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG CAPSULE;ORAL Prescription
200MG CAPSULE;ORAL Prescription

6. Drug name - XOFLUZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8987441 GENENTECH INC Substituted polycyclic carbamoyl pyridone derivative prodrug
Sep, 2031

(8 years from now)

US10392406 GENENTECH INC Substituted polycyclic pyridone derivatives and prodrugs thereof
Apr, 2036

(13 years from now)

US10759814 GENENTECH INC Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
Aug, 2037

(14 years from now)

CN112876473A GENENTECH INC Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof
Jun, 2022

(3 months ago)

CN103228653A GENENTECH INC Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug
Sep, 2031

(8 years from now)

CN103228653B GENENTECH INC Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug
Sep, 2031

(8 years from now)

CN112940010A GENENTECH INC Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof
Apr, 2036

(13 years from now)

CN112940010B GENENTECH INC Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof
Apr, 2036

(13 years from now)

CN113004304A GENENTECH INC Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof
Apr, 2036

(13 years from now)

CN113004304B GENENTECH INC Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof
Apr, 2036

(13 years from now)

IN201303057P4 GENENTECH INC Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug
Sep, 2031

(8 years from now)

IN318238B GENENTECH INC Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug
Sep, 2031

(8 years from now)

IN201747041390A GENENTECH INC Substituted Polycyclic Pyridone Derivative And Prodrug Thereof
Apr, 2036

(13 years from now)

IN346800B GENENTECH INC Substituted Polycyclic Pyridone Derivative And Prodrug Thereof
Apr, 2036

(13 years from now)

EP2620436A1 GENENTECH INC Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug
Sep, 2031

(8 years from now)

EP2620436A4 GENENTECH INC Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug
Sep, 2031

(8 years from now)

EP2620436B1 GENENTECH INC Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug
Sep, 2031

(8 years from now)

EP3428170A1 GENENTECH INC Anti-Influenza Polycyclic Pyridone Derivative And Prodrug Thereof
Apr, 2036

(13 years from now)

EP3428170B1 GENENTECH INC Anti-Influenza Polycyclic Pyridone Derivative And Prodrug Thereof
Apr, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9815835 GENENTECH INC Substituted polycyclic carbamolypyridone derivative Jun, 2030

(7 years from now)

US8927710 GENENTECH INC Substituted polycyclic carbamoylpyridone derivative May, 2031

(8 years from now)

US10633397 GENENTECH INC Substituted polycyclic pyridone derivatives and prodrugs thereof Apr, 2036

(13 years from now)

Drugs and Companies using BALOXAVIR MARBOXIL ingredient

Treatment: Method for treating influenza; method for post-exposure prophylaxis of influenza

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription
80MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.